Use of nirsevimab was found to be 89% effective against acute respiratory syncytial virus (RSV) infection and 93% effective against hospitalization among children younger than age 5 in a recent study published in JAMA Pediatrics. The study examined data in 7 academic pediatric medical centers in the United States from 2017 to 2020 and data from the 2023-2024 RSV season. It was only in July 2023—right before the 2023-2024 RSV season—that nirsevimab first became available. …
Read More